Stock XSPRAY XSPRAY PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Xspray Pharma AB

Equities

XSPRAY

SE0009973563

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:13:08 2024-04-26 am EDT 		5-day change 1st Jan Change
40.45 SEK +0.50% Intraday chart for Xspray Pharma AB +2.53% +1.12%
Feb. 14 Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Feb. 12 US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,394 3,665 1,326 1,293 1,250 1,264 - -
Enterprise Value (EV) 1 1,184 3,665 1,057 1,175 1,121 644.3 1,264 1,264
P/E ratio -27.6 x -63.6 x -12.7 x -9.12 x -5.92 x 1.89 x - -
Yield - - - - - 2.47% - -
Capitalization / Revenue - - - - - 9.65 x 1.6 x 0.79 x
EV / Revenue - - - - - 4.92 x 1.6 x 0.79 x
EV / EBITDA -28.3 x - -11.9 x -9.51 x -6.49 x -2.32 x 5.43 x 1.28 x
EV / FCF -9.38 x - -20 x - -5.44 x -1.69 x 14 x -
FCF Yield -10.7% - -5.01% - -18.4% -59.3% 7.12% -
Price to Book - - 2.24 x 2.33 x 1.53 x 0.67 x - -
Nbr of stocks (in thousands) 16,752 18,893 20,680 22,680 31,254 31,254 - -
Reference price 2 83.20 194.0 64.10 57.00 40.00 40.45 40.45 40.45
Announcement Date 2/28/20 2/25/21 2/18/22 2/15/23 2/14/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - 131 789 1,605
EBITDA 1 -41.76 - -89.08 -123.5 -172.5 -278 233 986
EBIT 1 -46.56 - -97.95 -133.1 -181.7 -293 214 946
Operating Margin - - - - - -223.66% 27.12% 58.94%
Earnings before Tax (EBT) 1 -45.77 - -96.7 -131.7 -179.7 754.4 - -
Net income 1 -45.77 -52.41 -96.7 -131.7 -179.7 596 - -
Net margin - - - - - 454.97% - -
EPS 2 -3.010 -3.050 -5.030 -6.250 -6.760 21.42 - -
Free Cash Flow 1 -126.2 - -52.92 - -206 -382 90 -
FCF margin - - - - - -291.6% 11.41% -
FCF Conversion (EBITDA) - - - - - - 38.63% -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 - - - - - 1.000 - -
Announcement Date 2/28/20 2/25/21 2/18/22 2/15/23 2/14/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4
Net sales - - - - -
EBITDA 1 -49.98 -16.96 -26.82 -26.6 -53.16
EBIT 1 -52.28 -19.28 -29.21 -28.99 -55.59
Operating Margin - - - - -
Earnings before Tax (EBT) 1 -51.94 -18.93 -28.86 -28.65 -55.22
Net income 1 -51.94 -18.93 -28.86 -28.65 -55.22
Net margin - - - - -
EPS 2 -2.620 -0.9200 -1.400 -1.390 -2.480
Dividend per Share - - - - -
Announcement Date 2/18/22 5/6/22 8/5/22 11/9/22 2/15/23
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 210 - 269 118 129 620 - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -126 - -52.9 - -206 -382 90 -
ROE (net income / shareholders' equity) -13.5% - - - - 55% - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - 28.60 24.50 26.10 60.40 - -
Cash Flow per Share - - - - - - - -
Capex 1 23.1 - 1.31 - 2.69 26 28 -
Capex / Sales - - - - - 19.85% 3.55% -
Announcement Date 2/28/20 2/25/21 2/18/22 2/15/23 2/14/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
40.45 SEK
Average target price
107 SEK
Spread / Average Target
+164.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
XSPRAY PHARMA AB Stock Xspray Pharma AB
+1.12% 115M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. XSPRAY Stock
  4. Financials Xspray Pharma AB